Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Recombinant
100%
Multiple Myeloma
100%
Bone Metastasis
100%
Phase I Study
100%
Breast Carcinoma
100%
Osteoprotegerin
100%
Bone Resorption
75%
Osteoclast
50%
Multiple Myeloma Patients
50%
Creatinine
25%
N-telopeptide
25%
Bone Metabolism
25%
Exclusion Criteria
25%
Doxorubicin
25%
Potential Therapeutics
25%
Chemotherapy
25%
Albumin
25%
Serum Calcium
25%
Randomized Double-blind
25%
Biologic Activity
25%
Radiation Therapy
25%
Congestive Heart Failure
25%
Lytic Bone Lesion
25%
Collagen
25%
Femur
25%
Herpes Zoster
25%
Double Dummy
25%
Terminal Differentiation
25%
Bone Disease
25%
Osteoprotegerin Ligand
25%
Decoy Receptor
25%
Dose-escalation Study
25%
NF-B
25%
Clinical Symptoms
25%
Serious Adverse Events
25%
Creatinine Level
25%
Surrogate Marker
25%
Dose-dependent
25%
Well Tolerated
25%
Medicine and Dentistry
Multiple Myeloma
100%
Bone Metastasis
100%
Pamidronic Acid
100%
Osteoprotegerin
100%
Breast Carcinoma
100%
Osteoclast Differentiation Factor
80%
Osteolysis
60%
Urinary System
40%
Single Drug Dose
40%
Osteoclast
40%
Receptor
40%
Creatinine
40%
Therapeutic Agent
20%
Isotopes of Calcium
20%
Adverse Event
20%
Doxorubicin
20%
Bone Lesion
20%
Telopeptide
20%
Disease Marker
20%
Disseminated Herpes Zoster
20%
Congestive Heart Failure
20%
Bone Remodeling
20%
Diseases
20%
Radiation Therapy
20%
Chemotherapy
20%
Bone Disease
20%
Exclusion Criterion
20%
Albumin
20%
Clinical Symptom
20%
Pharmacology, Toxicology and Pharmaceutical Science
Bone Metastasis
100%
Multiple Myeloma
100%
Pamidronic Acid
100%
Breast Carcinoma
100%
Osteoprotegerin
100%
Osteoclast Differentiation Factor
80%
Receptor
40%
Creatinine
40%
Telopeptide
20%
Adverse Event
20%
Bone Lesion
20%
Congestive Heart Failure
20%
Doxorubicin
20%
Herpes Zoster
20%
Disease Marker
20%
Chemotherapy Regimens
20%
Albumin
20%
Diseases
20%
Bone Disease
20%